China National Accord Medicines (SZSE:000028) Hasn't Managed To Accelerate Its Returns
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) an
Shareholders in China National Accord Medicines (SZSE:000028) Are in the Red If They Invested a Year Ago
While not a mind-blowing move, it is good to see that the China National Accord Medicines Corporation Ltd. (SZSE:000028) share price has gained 14% in the last three months. But in truth the last y
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
Sinopharm Holdings (01099): Sinopharm (000028.SZ)'s 2023 net profit of 1,599 billion yuan increased 7.57% year-on-year
Sinopharm Holdings (01099) issued an announcement. Sinopharm Group, a subsidiary of the company, is united Pharmaceutical Co., Ltd. (Sinopharm 1...
Sinopharm Holdings: Sinopharm's consistent annual net profit of 1,599 billion yuan increased 7.57% year-on-year
Sinopharm Holdings (01099) released Sinopharm's consistent (000028.SZ) annual performance report. The company achieved operating income of RMB 75.477 billion (same unit), up 2.77% year on year; operating profit of 2,467 billion yuan, up 7.00% year on year; total profit of 2,473 billion yuan, up 7.02% year on year; net profit attributable to shareholders of listed companies was 1,599 billion yuan, up 7.57% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,533 billion yuan, up 7.58% year on year; basic per share Earnings were 2.87 yuan.
Sinopharm (000028.SZ) performance report: 2023 net profit of 1,599 billion yuan increased 7.57% year-on-year
Gelonghui, March 14 | Sinopharm (000028.SZ) announced its 2023 annual results report. During the reporting period, the company achieved operating income of 75.477 billion yuan, up 2.77% year on year; total profit of 2,467 billion yuan, up 7.00% year on year; total profit of 2,473 billion yuan, up 10.54% year on year; net profit attributable to shareholders of listed companies was 1,598 billion yuan, up 7.57% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss 1,533 billion, a year-on-year increase
Is China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Most readers would already be aware that China National Accord Medicines' (SZSE:000028) stock increased significantly by 13% over the past three months. Given that stock prices are usually aligned w
Return Trends At China National Accord Medicines (SZSE:000028) Aren't Appealing
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. In a perfect world, we'd like to see a company investing mor
Private Companies Invested in China National Accord Medicines Corporation Ltd. (SZSE:000028) Copped the Brunt of Last Week's CN¥1.6b Market Cap Decline
Key Insights Significant control over China National Accord Medicines by private companies implies that the general public has more power to influence management and governance-related decisions Chi
Investors Aren't Buying China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Earnings
With a price-to-earnings (or "P/E") ratio of 9.5x China National Accord Medicines Corporation Ltd. (SZSE:000028) may be sending very bullish signals at the moment, given that almost half of all compan
Investors in China National Accord Medicines (SZSE:000028) Have Unfortunately Lost 21% Over the Last Three Years
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Returns On Capital At China National Accord Medicines (SZSE:000028) Have Hit The Brakes
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. Firstly, we'd want to identify a growing return on capital employ
Private Companies Account for 57% of China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Ownership, While Individual Investors Account for 31%
Key Insights Significant control over China National Accord Medicines by private companies implies that the general public has more power to influence management and governance-related decisions 57%
Sinopharm Unification (000028.SZ): Focus on main business pharmaceutical distribution and pharmaceutical retail to carry out related business
On November 1, Gelonghui, Sinopharm (000028.SZ) stated on the investor interactive platform that the company focuses on its main business, pharmaceutical distribution and pharmaceutical retail, to carry out related business.
China National Accord Medicines' Profit Slides 4% in Q3
China National Accord Medicines' (SHE:000028, SHE:200028) attributable net profit fell 3.75% year over year to 359.4 million yuan in the third quarter of 2023. Earnings per share for the July to Septe
Sinopharm's consistent (000028.SZ) released results for the first three quarters, with net profit of 1.19 billion yuan, an increase of 13.56% over the previous year
Sinopharm (000028.SZ) released its report for the first three quarters of 2023, with revenue of 56.586 billion yuan...
Are China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
China National Accord Medicines (SZSE:000028) has had a rough three months with its share price down 19%. However, the company's fundamentals look pretty decent, and long-term financials are usually
Sinopharm is consistent (000028.SZ): not engaged in securities financing business
Glonghui September 22丨Sinopharm (000028.SZ) stated on the investor interactive platform that the company is not engaged in securities financing business.
Sinopharm Holdings: Sinopharm's consistent mid-term net profit of 830 million yuan increased 23.14% year-on-year
Sinopharm Holdings (01099) announced the results of its subsidiary Sinopharm Group Congruent Pharmaceutical Co., Ltd. (000028.SZ)) for the half year ended June 30, 2023. The group achieved total operating income of 38.388 billion yuan (RMB, same below) during the period, an increase of 6.25% over the previous year; net profit attributable to shareholders of listed companies of 830 million yuan, an increase of 23.14%; basic earnings per share of 1.49 yuan.
Those Who Invested in China National Accord Medicines (SZSE:000028) a Year Ago Are up 49%
It hasn't been the best quarter for China National Accord Medicines Corporation Ltd. (SZSE:000028) shareholders, since the share price has fallen 29% in that time. While that might be a setback, it
No Data